Optune System + PEMBROLIZUMAB + Temozolomide for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Jan 2018: Trial registered, NCT03405792
  2. 23 Feb 2018: Trial started, NCT03405792

The trials

NCT03405792: Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

State
Under way
Phase
Phase 2
People
40 taking part
Started
23 Feb 2018
Primary completion
26 Nov 2022
Arms
Optune System combined with Temozolomide (TMZ) + Pembrolizumab
Results
Posted on the registry
  1. 23 Jan 2018: Trial registered
  2. 23 Feb 2018: Trial started
  3. 15 Apr 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.